Serologically documented loracarbef (Lorabid)-induced immune thrombocytopenia.
We report here the first case of severe immune thrombocytopenia induced by a second-generation cephalosporin antibiotic, Loracarbef. A 56-year old white female developed acute severe thrombocytopenia associated with acute respiratory symptoms following administration of Loracarbef. She responded to Loracarbef withdrawal and systemic corticosteroid administration. Loracarbef-dependent platelet-reactive antibodies were demonstrable in her serum by flow cytometry.
Aljitawi
O S
OS
Division of Hematology/Oncology and Department of Internal Medicine, James H. Quillen College of Medicine, East Tennessee State University, Building 1, Dogwood Avenue, Johnson City, TN 37614, USA.
Krishnan
K
K
Curtis
B R
BR
Bougie
D W
DW
Aster
R H
RH
D001323:Autoantibodies / Q000097:blood; D001792:Blood Platelets / Q000276:immunology; D002511:Cephalosporins / Q000009:adverse effects*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000139:chemically induced* / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy
D001323:Autoantibodies; D002511:Cephalosporins; C054920:loracarbef; D008775:Methylprednisolone